Does “march in” authority have hope for bringing drug prices down? Should it? What are the secondary effects of changing who can produce what drugs? Cato’s Michael Cannon and Peter Van Doren comment.
Biden Wants to ‘March In’ to Fix Drug Prices
Your favorite podcast, in your inbox.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.